Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

Resverlogix (TSX:RVX) posts promising COVID-19 treatment findings

Isabella Zavarise December 23, 2020

Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen

GlobeNewswire December 22, 2020

Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection - Confirms Plans for COVID-19 Clinical Trial

GlobeNewswire December 22, 2020

Resverlogix Files Notice of Annual and Special Meeting of Shareholders

GlobeNewswire November 20, 2020

Zenith Files Notice of Annual and Special Meeting of Shareholders

GlobeNewswire November 20, 2020

Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics

GlobeNewswire November 12, 2020

Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers

GlobeNewswire November 2, 2020

Zenith Confirms Interim Filings on SEDAR

GlobeNewswire October 28, 2020

A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

GlobeNewswire October 26, 2020

Resverlogix Announces Presentations at Leading Scientific Conferences

GlobeNewswire October 15, 2020

Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet

GlobeNewswire October 14, 2020

Zenith Provides Update Regarding Extension of its Filing Calendar

GlobeNewswire October 9, 2020

Resverlogix Announces $13 Million Private Placement

GlobeNewswire October 6, 2020

Resverlogix Confirms Interim Filings on SEDAR

GlobeNewswire October 2, 2020

Resverlogix Provides Update Regarding Extension of its Filing Calendar

GlobeNewswire September 25, 2020

Resverlogix Announces Publication in High-impact Peer-reviewed Journal - Medicinal Research Reviews

GlobeNewswire September 15, 2020

Resverlogix Provides Update Regarding Extension of its Filing Calendar

GlobeNewswire September 11, 2020

Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum ("GCFF") Virtual Conference 2020 - Investing in Innovation

GlobeNewswire September 8, 2020

Resverlogix Provides Update Regarding Extension of its Filing Calendar

GlobeNewswire August 28, 2020

Zenith Announces Extension of its Filing Calendar Based on Continuous Disclosure Exemption

GlobeNewswire August 26, 2020